This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gary L. Buchschacher, Jr, PhD

JAMA. 1993;269(22):2880-2886.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE ACQUIRED immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus (HIV), is a chronic disease primarily characterized by a decrease in CD4-positive T lymphocytes. Subsequent immune system suppression and failure lead to frequent infection by opportunistic pathogens and, oftentimes along with neoplasms or other HIV-related pathology, death of the patient. During the last 10 years, considerable progress has been made in the development of treatments for various opportunistic infections. In addition, the use of nucleoside analogs (zidovudine, dideoxyinosine, dideoxycytodine), which interfere with reverse transcription and seem to slow viral spread, has become commonplace. Although these treatments can delay disease progression,¹ side effects associated with their use, and possibly the development of viral resistance to these drugs,² may inevitably lead to treatment failure.

For these reasons, alternate therapies for HIV infection are needed. Included among the list of potential treatments is gene transfer therapy. Recent progress in ongoing clinical . . . [Full Text PDF of this Article]

Author Affiliations
From the McArdle Laboratory for Cancer Research and the MD/PhD Integrated Degree Program, University of Wisconsin, Madison.

Footnotes
Reprint requests to McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Ave, Madison, WI 53706 (Dr Buchschacher).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?